[1]
|
Qiu, H., Cao, S. and Xu, R. (2021) Cancer Incidence, Mortality, and Burden in China: A Time-trend Analysis and Comparison with the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Communications, 41, 1037-1048. https://doi.org/10.1002/cac2.12197
|
[2]
|
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
|
[3]
|
凌徐心仪, 张瑶, 钟华. 非小细胞肺癌免疫治疗获益人群筛选的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(8): 1114-1119.
|
[4]
|
Carron, R., Gaudy-Marqueste, C., Amatore, F., Padovani, L., Malissen, N., Balossier, A., et al. (2020) Stereotactic Radiosurgery Combined with Anti-PD1 for the Management of Melanoma Brain Metastases: A Retrospective Study of Safety and Efficacy. European Journal of Cancer, 135, 52-61. https://doi.org/10.1016/j.ejca.2020.04.028
|
[5]
|
Backlund, E., Grozman, V., Egyhazi Brage, S., Lewensohn, R., Lindberg, K. and Helgadottir, H. (2023) Radiotherapy with or without Immunotherapy in Metastatic Melanoma: Efficacy and Tolerability. Acta Oncologica, 62, 1921-1930. https://doi.org/10.1080/0284186x.2023.2280766
|
[6]
|
Theelen, W.S.M.E., Peulen, H.M.U., Lalezari, F., van der Noort, V., de Vries, J.F., Aerts, J.G.J.V., et al. (2019) Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 5, 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478
|
[7]
|
Yin, L., Xue, J., Li, R., Zhou, L., Deng, L., Chen, L., et al. (2020) Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients with Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 108, 212-224. https://doi.org/10.1016/j.ijrobp.2020.05.002
|
[8]
|
Brooks, E.D. and Chang, J.Y. (2018) Time to Abandon Single-Site Irradiation for Inducing Abscopal Effects. Nature Reviews Clinical Oncology, 16, 123-135. https://doi.org/10.1038/s41571-018-0119-7
|
[9]
|
Herrera, F.G., Ronet, C., Ochoa de Olza, M., Barras, D., Crespo, I., Andreatta, M., et al. (2021) Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 12, 108-133. https://doi.org/10.1158/2159-8290.cd-21-0003
|
[10]
|
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., et al. (2021) Vascular Normalization in Immunotherapy: A Promising Mechanisms Combined with Radiotherapy. Biomedicine & Pharmacotherapy, 139, Article ID: 111607. https://doi.org/10.1016/j.biopha.2021.111607
|
[11]
|
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., et al. (2017) Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming. Nature, 544, 250-254. https://doi.org/10.1038/nature21724
|
[12]
|
Chen, J.L., Pan, C., Huang, Y., Tsai, C., Wang, C., Lin, Y., et al. (2020) Evaluation of Antitumor Immunity by a Combination Treatment of High-Dose Irradiation, Anti-PDL1, and Anti-Angiogenic Therapy in Murine Lung Tumors. Cancer Immunology, Immunotherapy, 70, 391-404. https://doi.org/10.1007/s00262-020-02690-w
|
[13]
|
Robinson, C.G., DeWees, T.A., El Naqa, I.M., Creach, K.M., Olsen, J.R., Crabtree, T.D., et al. (2013) Patterns of Failure after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 8, 192-201. https://doi.org/10.1097/jto.0b013e31827ce361
|
[14]
|
Strauss, G.M., Herndon, J.E., Maddaus, M.A., Johnstone, D.W., Johnson, E.A., Harpole, D.H., et al. (2008) Adjuvant Paclitaxel plus Carboplatin Compared with Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology, 26, 5043-5051. https://doi.org/10.1200/jco.2008.16.4855
|
[15]
|
Altorki, N.K., McGraw, T.E., Borczuk, A.C., Saxena, A., Port, J.L., Stiles, B.M., et al. (2021) Neoadjuvant Durvalumab with or without Stereotactic Body Radiotherapy in Patients with Early-Stage Non-Small-Cell Lung Cancer: a Single-Centre, Randomised Phase 2 Trial. The Lancet Oncology, 22, 824-835. https://doi.org/10.1016/s1470-2045(21)00149-2
|
[16]
|
Kelly, K., Chansky, K., Gaspar, L.E., Albain, K.S., Jett, J., Ung, Y.C., et al. (2008) Phase III Trial of Maintenance Gefitinib or Placebo after Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: Swog S0023. Journal of Clinical Oncology, 26, 2450-2456. https://doi.org/10.1200/jco.2007.14.4824
|
[17]
|
Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/nejmoa1809697
|
[18]
|
Durm, G.A., Jabbour, S.K., Althouse, S.K., Liu, Z., Sadiq, A.A., Zon, R.T., et al. (2020) A Phase 2 Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14‐179. Cancer, 126, 4353-4361. https://doi.org/10.1002/cncr.33083
|
[19]
|
Jabbour, S.K., Berman, A.T., Decker, R.H., Lin, Y., Feigenberg, S.J., Gettinger, S.N., et al. (2020) Phase 1 Trial of Pembrolizumab Administered Concurrently with Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 6, 848-855. https://doi.org/10.1001/jamaoncol.2019.6731
|
[20]
|
Werner-Wasik, M., Swann, R.S., Bradley, J., Graham, M., Emami, B., Purdy, J., et al. (2008) Increasing Tumor Volume Is Predictive of Poor Overall and Progression-free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II Radiation Dose-Escalation Study in Patients with Inoperable Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 70, 385-390. https://doi.org/10.1016/j.ijrobp.2007.06.034
|
[21]
|
Wang, Y., Zhang, T., Wang, J., Zhou, Z., Liu, W., Xiao, Z., et al. (2023) Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients with Bulky Unresectable Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 116, 590-600. https://doi.org/10.1016/j.ijrobp.2022.12.042
|
[22]
|
Wang, Y., Deng, L., Wang, J., Zhang, T., Wang, W., Wang, X., et al. (2024) Induction PD-1 Inhibitor Toripalimab plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidation Toripalimab for Bulky Locally Advanced Non-Small-Cell Lung Cancer: Protocol for a Randomized Phase II Trial (InTRist Study). Frontiers in Immunology, 14, Article ID: 1341584. https://doi.org/10.3389/fimmu.2023.1341584
|
[23]
|
Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., et al. (2022) Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 386, 1973-1985. https://doi.org/10.1056/nejmoa2202170
|
[24]
|
Wang, Z., Wu, L., Li, B., Cheng, Y., Li, X., Wang, X., et al. (2023) Toripalimab plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (Choice-01). Journal of Clinical Oncology, 41, 651-663. https://doi.org/10.1200/jco.22.00727
|
[25]
|
Zhu, X., Sun, L., Song, N., He, W., Xie, B., Hu, J., et al. (2022) Safety and Effectiveness of Neoadjuvant PD-1 Inhibitor (Toripalimab) plus Chemotherapy in Stage II-III NSCLC (LungMate 002): An Open-Label, Single-Arm, Phase 2 Trial. BMC Medicine, 20, Article No. 493. https://doi.org/10.1186/s12916-022-02696-4
|
[26]
|
Shaverdian, N., Lisberg, A.E., Bornazyan, K., Veruttipong, D., Goldman, J.W., Formenti, S.C., et al. (2017) Previous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the Keynote-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. https://doi.org/10.1016/s1470-2045(17)30380-7
|
[27]
|
Theelen, W.S.M.E., Peulen, H.M.U., Lalezari, F., van der Noort, V., de Vries, J.F., Aerts, J.G.J.V., et al. (2019) Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 5, 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478
|
[28]
|
Rudin, C.M., Awad, M.M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., et al. (2020) Pembrolizumab or Placebo plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III Keynote-604 Study. Journal of Clinical Oncology, 38, 2369-2379. https://doi.org/10.1200/jco.20.00793
|
[29]
|
Bauml, J.M., Mick, R., Ciunci, C., Aggarwal, C., Davis, C., Evans, T., et al. (2019) Pembrolizumab after Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. JAMA Oncology, 5, 1283-1290. https://doi.org/10.1001/jamaoncol.2019.1449
|
[30]
|
Hwang, W.L., Pike, L.R.G., Royce, T.J., Mahal, B.A. and Loeffler, J.S. (2018) Safety of Combining Radiotherapy with Immune-Checkpoint Inhibition. Nature Reviews Clinical Oncology, 15, 477-494. https://doi.org/10.1038/s41571-018-0046-7
|
[31]
|
Kadera, B.E., Li, L., Toste, P.A., Wu, N., Adams, C., Dawson, D.W., et al. (2013) Microrna-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis. PLOS ONE, 8, e71978. https://doi.org/10.1371/journal.pone.0071978
|
[32]
|
Levy, A., Massard, C., Soria, J. and Deutsch, E. (2016) Concurrent Irradiation with the Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Blocker Durvalumab: Single Centre Subset Analysis from a Phase 1/2 Trial. European Journal of Cancer, 68, 156-162. https://doi.org/10.1016/j.ejca.2016.09.013
|
[33]
|
Hwang, W.L., Niemierko, A., Hwang, K.L., Hubbeling, H., Schapira, E., Gainor, J.F., et al. (2018) Clinical Outcomes in Patients with Metastatic Lung Cancer Treated with PD-1/PD-l1 Inhibitors and Thoracic Radiotherapy. JAMA Oncology, 4, 253-255. https://doi.org/10.1001/jamaoncol.2017.3808
|
[34]
|
Tian, S., Switchenko, J.M., Buchwald, Z.S., Patel, P.R., Shelton, J.W., Kahn, S.E., et al. (2020) Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. International Journal of Radiation Oncology Biology Physics, 108, 304-313. https://doi.org/10.1016/j.ijrobp.2019.12.030
|